Article Text
Brief report
Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin)
Abstract
There are several good reasons for the UK Department of Health to recommend the appraisal of bevacizumab for the treatment of eye conditions by the National Institute for Health and Clinical Excellence. These reasons will extend to other drugs when similar situations arise in the future.
- Bioethics
- chemical and biological weapons
- drugs and drug industry
- international affairs